🟢 Moderna is trading 5% up as investors reassess Phase 3 melanoma-vaccine results

Moderna is trading 4.79% up at $224.43 on October 29, 2026, as investors continue to reassess its Phase 3 melanoma-vaccine results.

• Coverage links the rebound to data formally presented at ESMO and published in The New England Journal of Medicine.
• One report said the treatment reduced recurrence or death risk by 42% versus Keytruda alone.
• Earlier trading was volatile, and analyst views on valuation were mixed; no separate October 29 announcement or live volume details were identified.